Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of ruxolitinib cream in Chinese patients with nonsegmental vitiligo
CTR20240457Phase 3Active
- Sponsor
- Incyte
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in nonsegmental vitiligo, sponsored by Incyte. Started Mar 2024; status: active.
02
Drugs
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20240457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240457.